Hyderabad, March 20, 2026 – Natco Pharma Limited (BSE: 524816 | NSE: NATCOPHARM), a leading Indian pharmaceutical company, today announced the launch of generic Semaglutide Injection in multi-dose vial format in the Indian market, effective immediately following the Day 1 patent expiry.
Natco received Central Drugs Standard Control Organisation (CDSCO) approval in February 2026 to manufacture and market generic Semaglutide in both multi-dose vial and pen device formats based on successful clinical comparison studies. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus insufficiently controlled on existing therapy.
Product & Pricing Details
Natco is introducing Semaglutide under the brand names SEMANAT™ and SEMAFULLT™ in the following multi-dose vial strengths:
- 2 mg / 1.5 ml – MRP ₹1,290 per month
- 4 mg / 3 ml – MRP ₹1,290 per month
- 8 mg / 3 ml – MRP ₹1,750 per month
The multi-dose vial format includes customised syringes for accurate dosing and is positioned as the most affordable GLP-1 RA therapy currently available in India.
- Approximately 70% cheaper than pen-device formats
- Approximately 90% cheaper than the innovator’s branded product
The pen device format (2 mg/1.5 ml, 4 mg/3 ml, 8 mg/3 ml) is priced at MRP ₹4,000–4,500 per month and is expected to be launched in April 2026.
Natco is the first company in India to offer generic Semaglutide in multi-dose vial form and is also making the product available to third parties for co-marketing.
Strategic Impact
This launch significantly improves patient accessibility and long-term compliance to GLP-1 receptor agonist therapy in India. By offering a substantially lower-cost alternative in vial format, Natco aims to expand access to this important class of medicines for millions of people living with type 2 diabetes.
Commenting on the launch, a Natco spokesperson said: “We are proud to bring one of the most effective GLP-1 therapies to Indian patients at the most affordable price point in the market. The multi-dose vial format with customised syringes makes treatment more accessible and convenient, especially for patients in semi-urban and rural areas. This is yet another example of Natco’s commitment to bridging affordability gaps while maintaining world-class quality.”
About Natco Pharma Limited
Natco Pharma Limited is a vertically integrated pharmaceutical company focused on research, development, manufacturing, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs). The company has a strong presence in oncology, cardiology, diabetology, gastroenterology, and other chronic therapies. Natco operates multiple USFDA, MHRA, and WHO-GMP approved manufacturing facilities in India and exports to over 40 countries.
For more information, visit: www.natcopharma.co.in
Media & Investor Contact Natco Pharma Limited Email: investor@natcopharma.co.in
